Comparative Pharmacology
Head-to-head clinical analysis: ALREX versus HMS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALREX versus HMS.
ALREX vs HMS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory mediators.
HMS is a synthetic androgen and anabolic steroid that acts as an agonist at androgen receptors, promoting protein synthesis and muscle growth.
1-2 drops in the affected eye(s) four times daily; in severe cases, may be increased to 1-2 drops every hour during the first 24-48 hours.
No established standard dosing for HMS as it is not a recognized therapeutic agent. Please verify the drug name.
None Documented
None Documented
Approximately 1.6 hours (range 1.2–2.2 hours) for the active metabolite loteprednol etabonate; short half-life allows for BID dosing with minimal systemic accumulation.
3–5 hours; prolonged in renal impairment (up to 15 hours), requiring dose adjustment
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Fecal elimination accounts for the remainder via biliary excretion.
Renal (70% unchanged), biliary/fecal (20% as metabolites), 10% other
Category C
Category C
Corticosteroid (Ophthalmic)
Corticosteroid (Ophthalmic)